PMID- 23342255
OWN - NLM
STAT- MEDLINE
DCOM- 20140117
LR  - 20221207
IS  - 2045-7634 (Print)
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 1
IP  - 1
DP  - 2012 Aug
TI  - RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung 
      cancer.
PG  - 68-75
LID - 10.1002/cam4.13 [doi]
AB  - RET encodes the tyrosine kinase receptor of growth factors belonging to the 
      glial-derived neurotrophic factor family. Recently, RET gene rearrangements with 
      N-terminal of KIF5B gene were identified in lung adenocarcinomas from large-scale 
      sequencing. We investigated RET mRNA expression by real-time 
      reverse-transcriptase polymerase chain reaction (RT-PCR) assay using LightCycler, 
      and KIF5B/RET gene rearrangements using newly established fluorescence in situ 
      hybridization (FISH) analysis in surgically treated nonsmall cell lung cancer 
      (NSCLC) cases. RET protein expression was also investigated by 
      immunohistochemistry (IHC). This study included 157 surgically removed NSCLC 
      cases for mRNA level analyses. The RET/beta actin mRNA levels were not significantly 
      different between lung cancer (6.359 +/- 15.268) and adjacent normal lung tissues 
      (8.205 +/- 28.931, P = 0.6332). Tumor/normal (T/N) ratio of RET/beta actin mRNA levels 
      was not different within gender, stage, smoking status, and pathological 
      subtypes. T/N ratio of RET/beta actin mRNA levels was significantly higher in 
      KIF5B/RET rearrangement samples (161.763 +/- 123.488) than in wild-type samples 
      (5.9013 +/- 17.148, P = 0.044). Although RET IHC positivity was not perfectly 
      correlated with KIF5B/RET arrangement, we have detected the KIF5B/RET 
      rearrangements using FISH analysis. Thus, we have successfully introduced FISH 
      for diagnosing KIF5B/RET positive lung adenocarcinoma. This method facilitates 
      the molecular evaluation for RET fusions and could be applicable in clinical 
      practice to detect lung cancer that may be responsive to RET inhibitors.
FAU - Sasaki, Hidefumi
AU  - Sasaki H
AD  - Department of Oncology, Immunology, and Surgery, Nagoya City University Graduate 
      School of Medical Sciences Nagoya, Japan. hisasaki@med.nagoya-cu.ac.jp
FAU - Shimizu, Shigeki
AU  - Shimizu S
FAU - Tani, Yoichi
AU  - Tani Y
FAU - Maekawa, Masahiko
AU  - Maekawa M
FAU - Okuda, Katsuhiro
AU  - Okuda K
FAU - Yokota, Keisuke
AU  - Yokota K
FAU - Shitara, Masayuki
AU  - Shitara M
FAU - Hikosaka, Yu
AU  - Hikosaka Y
FAU - Moriyama, Satoru
AU  - Moriyama S
FAU - Yano, Motoki
AU  - Yano M
FAU - Fujii, Yoshitaka
AU  - Fujii Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120712
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (KIF5B protein, human)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 3.6.4.4 (Kinesins)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - Female
MH  - *Gene Expression
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Japan
MH  - Kinesins/*genetics/metabolism
MH  - Lung Neoplasms/diagnosis/*genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Proto-Oncogene Proteins c-ret/*genetics/metabolism
MH  - RNA, Messenger/genetics
MH  - Translocation, Genetic
PMC - PMC3544433
OTO - NOTNLM
OT  - FISH
OT  - KIF5B/RET
OT  - RET expression
OT  - lung cancer
EDAT- 2013/01/24 06:00
MHDA- 2013/01/24 06:01
PMCR- 2012/08/01
CRDT- 2013/01/24 06:00
PHST- 2012/03/21 00:00 [received]
PHST- 2012/05/30 00:00 [revised]
PHST- 2012/05/31 00:00 [accepted]
PHST- 2013/01/24 06:00 [entrez]
PHST- 2013/01/24 06:00 [pubmed]
PHST- 2013/01/24 06:01 [medline]
PHST- 2012/08/01 00:00 [pmc-release]
AID - 10.1002/cam4.13 [doi]
PST - ppublish
SO  - Cancer Med. 2012 Aug;1(1):68-75. doi: 10.1002/cam4.13. Epub 2012 Jul 12.